6 December 2018
ResistancePlus® GC receives CE-IVD mark
SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually...
15 November 2018
Johns Hopkins raising awareness of Mycoplasma genitalium resistance test for reproductive health
Dr. Maria Trent, a Professor of Pediatrics and Public Health at Johns Hopkins Medicine, is spearheading efforts to raise awareness...
12 November 2018
SpeeDx broaden European Distribution Network
SpeeDx have signed of a further four distribution partners, in preparation to strengthen representation across Europe. Axonlab (Germany, Benelux and...
15 October 2018
Draft BASHH gonorrhoea guidelines recommend ciprofloxacin susceptibility testing
Updated Draft BASHH guidelines on the management of gonorrhoea indicate ciprofloxacin as preferential treatment over ceftriaxone if susceptibility is known. ResistancePlus®...
26 September 2018
SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG
SpeeDx announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG. "This test is an exciting...
25 July 2018
UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance
The British Association of Sexual Health and HIV (BASHH) draft guidelines for Mycoplasma genitalium (Mgen) were posted for consultation and...
